Key Highlights

  • Prime Medicine (NASDAQ:PRME) climbed 77.19% over one month in published market data as of October 28, 2026, including 28.83% in the latest week and 16.09% in the latest session.
  • On October 5, 2026 the company announced the first patient dosed in a global Phase 1/2 trial of PM577a for Wilson disease, with initial clinical data expected in 2027.
  • A reported FDA clearance of the investigational new drug application for PM647 in alpha-1 antitrypsin deficiency followed on October 6, and Oppenheimer reiterated Outperform with a USD 11 target.
  • Cash was USD 108.8 million at June 30, 2026 and funds operations into 2027, so Prime Medicine (NASDAQ:PRME) faces financing needs and possible dilution, as reported.

The October Milestones

Prime Medicine (NASDAQ:PRME) develops prime editing, a gene editing approach designed to correct mutations in the body without cutting both DNA strands. On October 5, 2026 it said the first patient had been dosed with PM577a, an in vivo prime editor for Wilson disease patients carrying the H1069Q mutation in the ATP7B gene. The open-label study is registered as NCT07748403, focuses on safety and tolerability, and tracks copper measures as preliminary efficacy. The FDA also granted Rare Pediatric Disease designation to PM577. A report on October 6 said the FDA cleared the IND for PM647 in alpha-1 antitrypsin deficiency. Chief Executive Allan Reine called the dosing a meaningful step toward a one-time treatment for Wilson disease.

Pipeline and Cash

In the second quarter of 2026 the company reported a net loss of USD 42.1 million and cash of USD 108.8 million, down from USD 191.4 million at the end of 2025. An arbitration over PM647 was resolved in its favor in July 2026, with no monetary damages owed. PM359 for chronic granulomatous disease received FDA RMAT designation in June 2026, and a BLA submission is planned for the first half of 2027, pending FDA discussions. Collaboration revenue from a large pharmaceutical partner was USD 1.2 million. First clinical data for PM577a and PM647 are expected in 2027. Both liver programs use the same lipid nanoparticle delivery platform, which concentrates platform risk across them.

Risks and Next Steps

Cash into 2027 is short for a company whose first data arrive in 2027, so a financing is likely, and Oppenheimer itself noted share-price weakness and financing pressure. First-in-human trials carry safety and editing efficiency risk that could reverse the rally. The stock gained 66.12% over three months and 44.29% year to date, and rose 16.09% on October 28 for which no company announcement was found. Wilson disease and alpha-1 antitrypsin deficiency are rare, and approvals remain years away. Prime Medicine (NASDAQ:PRME) investors should watch the third quarter report and any equity raise. Oppenheimer's USD 11 target is more than double the latest quote of USD 5.05, but targets are opinions, not forecasts, and can change after a financing.

Where Things Stand

Prime Medicine (NASDAQ:PRME) rose 77.19% because first patient dosing for Wilson disease and the reported FDA clearance for PM647 moved two programs into the clinic, lifting a stock that had recently traded between about USD 2.77 and USD 3.72. The case for further gains rests on 2027 clinical data, a year away, while cash runs into 2027. The balance of evidence favors a milestone-driven rally with a financing overhang. The next test is the third quarter report and any capital raise.